Global Sickle Cell Disease Treatment Market Growth (Status and Outlook) 2023-2029

Global Sickle Cell Disease Treatment Market Growth (Status and Outlook) 2023-2029

Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorderhave atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.

LPI (LP Information)' newest research report, the “Sickle Cell Disease Treatment Industry Forecast” looks at past sales and reviews total world Sickle Cell Disease Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Sickle Cell Disease Treatment sales for 2023 through 2029. With Sickle Cell Disease Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sickle Cell Disease Treatment industry.

This Insight Report provides a comprehensive analysis of the global Sickle Cell Disease Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sickle Cell Disease Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sickle Cell Disease Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sickle Cell Disease Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sickle Cell Disease Treatment.

The global Sickle Cell Disease Treatment market size is projected to grow from US$ 1878.5 million in 2022 to US$ 4118.4 million in 2029; it is expected to grow at a CAGR of 11.9% from 2023 to 2029.

United States market for Sickle Cell Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Sickle Cell Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Sickle Cell Disease Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Sickle Cell Disease Treatment players cover AstraZeneca, Eli Lilly, Novartis, Pfizer, Baxter, Emmaus Life Sciences, Bluebird bio, Blood Therapeutics and Sangamo Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Sickle Cell Disease Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Sickle Cell Anemia
Sickle Beta Thalassemia
Sickle Hemoglobin C Disease

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Eli Lilly
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird bio
Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Sanofi
CRISPR Therapeutics
Vertex Pharmaceuticals, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.